Soleno Therapeutics, Inc. (SLNO) 10-Year Financial Performance & Capital Metrics

SLNO • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutSoleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.Show more

Revenue $0
EBITDA -$186M -371.0%
Net Income -$176M -351.0%
EPS (Diluted) -4.38 -85.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -87.35% -88.0%
ROIC -142%
Debt/Equity 0.22 +8321.9%
Interest Coverage -812.43

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 9 (bottom 9%)
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM40.19%

EPS CAGR

10Y-

5Y-

3Y-

TTM46.1%

ROCE

10Y Avg-103.84%

5Y Avg-74.56%

3Y Avg-75.44%

Latest-77.97%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	387.56K	1.45M	-1.55B	0	0	0	0	0	0	0
Revenue Growth %	-	2.74%	-1071.45%	1%	-	-	-	-	-	-
Cost of Goods Sold+	352.68K	1.51M	1.61M	1.92M	2.3M	2.19M	0	0	0	0
COGS % of Revenue	0.91%	1.04%	-0%	-	-	-	-	-	-	-
Gross Profit+	34.87K	-58.52K	-1.55B	-1.92M	-2.3M	-2.19M	0	0	0	0
Gross Margin %	0.09%	-0.04%	1%	-	-	-	-	-	-	-
Gross Profit Growth %	-	-2.68%	-26565.41%	1%	-0.2%	0.04%	1%	-	-	-
Operating Expenses+	12.19M	13.55M	9.68M	13.73M	20.9M	29.75M	31.53M	24.4M	41.38M	187.67M
OpEx % of Revenue	31.47%	9.34%	-0.01%	-	-	-	-	-	-	-
Selling, General & Admin	7.88M	8.37M	6.61M	6.56M	4.63M	6.56M	10.81M	9.84M	13.48M	105.86M
SG&A % of Revenue	20.33%	5.77%	-0%	-	-	-	-	-	-	-
Research & Development	4.54M	5.18M	3.07M	7.18M	16.27M	23.19M	21.45M	15.27M	25.19M	78.57M
R&D % of Revenue	11.7%	3.57%	-0%	-	-	-	-	-	-	-
Other Operating Expenses	-183.56K	-100.52K	-585.95K	6K	0	0	-731K	-712K	2.71M	3.24M
Operating Income+	-12.16M	-13.61M	-12.17M	-14.3M	-23.2M	-31.95M	-31.53M	-24.4M	-41.38M	-187.67M
Operating Margin %	-31.38%	-9.38%	0.01%	-	-	-	-	-	-	-
Operating Income Growth %	-1.36%	-0.12%	0.11%	-0.17%	-0.62%	-0.38%	0.01%	0.23%	-0.7%	-3.53%
EBITDA+	-12.05M	-13.59M	-10.56M	-12.38M	-20.9M	-29.75M	-29.57M	-22.43M	-39.43M	-185.68M
EBITDA Margin %	-31.1%	-9.37%	0.01%	-	-	-	-	-	-	-
EBITDA Growth %	-1.35%	-0.13%	0.22%	-0.17%	-0.69%	-0.42%	0.01%	0.24%	-0.76%	-3.71%
D&A (Non-Cash Add-back)	108.23K	19.7K	1.61M	1.92M	2.3M	2.19M	1.96M	1.96M	1.96M	1.99M
EBIT	-12.16M	-6.74M	-13.44M	-13.73M	-30.77M	-24.64M	-32.26M	-24.07M	-38.99M	-175.62M
Net Interest Income+	-3.05M	0	0	0	154K	13K	110K	300K	2.58M	11.82M
Interest Income	0	0	0	0	154K	13K	110K	300K	2.58M	12.05M
Interest Expense	3.05M	0	0	62K	0	0	0	0	0	231K
Other Income/Expense	-3.75M	1.59M	-1.27M	2.46M	-7.58M	7.31M	618K	330K	2.4M	11.82M
Pretax Income+	-15.91M	-12.04M	-13.72M	-11.84M	-30.77M	-24.64M	-30.91M	-24.07M	-38.99M	-175.85M
Pretax Margin %	-41.05%	-8.3%	0.01%	-	-	-	-	-	-	-
Income Tax+	0	21.7K	-1.65M	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1.14%	1.13%	1%	1%	1%	1%	1%	1%
Net Income+	-15.91M	-12.07M	-15.67M	-13.34M	-30.77M	-24.64M	-30.91M	-24.07M	-38.99M	-175.85M
Net Margin %	-41.05%	-8.32%	0.01%	-	-	-	-	-	-	-
Net Income Growth %	-0.15%	0.24%	-0.3%	0.15%	-1.31%	0.2%	-0.25%	0.22%	-0.62%	-3.51%
Net Income (Continuing)	-15.91M	-6.74M	-11.79M	-11.84M	-30.77M	-24.64M	-30.91M	-24.07M	-38.99M	-175.85M
Discontinued Operations	0	-5.33M	-3.59M	-1.49M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-126.58	-58.35	-26.18	-9.54	-15.78	-3.68	-5.81	-2.87	-2.36	-4.38
EPS Growth %	0.85%	0.54%	0.55%	0.64%	-0.65%	0.77%	-0.58%	0.51%	0.18%	-0.86%
EPS (Basic)	-126.58	-58.35	-26.18	-9.54	-15.78	-3.68	-5.81	-2.87	-2.36	-4.38
Diluted Shares Outstanding	125.68K	206.77K	598.52K	1.4M	2.28M	4.17M	5.32M	8.4M	16.49M	40.18M
Basic Shares Outstanding	125.68K	206.77K	598.52K	1.4M	2.28M	4.17M	5.32M	8.4M	16.49M	40.18M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.4M	3.8M	17.99M	24.67M	21.14M	50.24M	22.42M	15.65M	171.36M	293.89M
Cash & Short-Term Investments	5.49M	2.73M	17.1M	24.08M	20.73M	49.22M	21.3M	14.6M	169.68M	291.44M
Cash Only	5.49M	2.73M	17.1M	23.1M	20.73M	49.22M	21.3M	14.6M	169.68M	87.93M
Short-Term Investments	0	0	0	978K	0	0	0	0	0	203.51M
Accounts Receivable	156.13K	133.34K	0	64K	0	0	0	0	0	0
Days Sales Outstanding	147.04	33.55	-	-	-	-	-	-	-	-
Inventory	551.01K	660.39K	0	0	0	0	0	0	0	0
Days Inventory Outstanding	570.25	159.7	-	-	-	-	-	-	-	-
Other Current Assets	35K	695.39K	551K	0	0	0	0	1.04M	1.68M	2.45M
Total Non-Current Assets+	1.8M	1.76M	21.03M	18.48M	17.03M	14.74M	13.13M	10.85M	9.33M	37.08M
Property, Plant & Equipment	85.75K	102.56K	22.89K	12K	444K	158K	454K	157K	419K	2.98M
Fixed Asset Turnover	4.52x	14.15x	-67861.13x	-	-	-	-	-	-	-
Goodwill	718K	718K	125.53K	0	0	0	0	0	0	0
Intangible Assets	916.81K	817.47K	20.41M	18.47M	16.52M	14.58M	12.64M	10.69M	8.75M	6.8M
Long-Term Investments	0	0	0	0	0	0	0	0	0	27.21M
Other Non-Current Assets	76.34K	125.53K	591.92K	0	59K	0	40K	0	165K	83K
Total Assets+	8.2M	5.56M	39.02M	43.15M	38.17M	64.98M	35.55M	26.5M	180.69M	330.97M
Asset Turnover	0.05x	0.26x	-39.80x	-	-	-	-	-	-	-
Asset Growth %	-0.02%	-0.32%	6.01%	0.11%	-0.12%	0.7%	-0.45%	-0.25%	5.82%	0.83%
Total Current Liabilities+	3.19M	1.71M	1.73M	1.88M	4.96M	8.62M	8.01M	7.31M	11.51M	18.75M
Accounts Payable	495.34K	410.51K	633K	934K	2M	3.49M	3.25M	1.78M	3.15M	8.88M
Days Payables Outstanding	512.64	99.28	143.42	177.65	317.01	580.44	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	2.18M	246.4K	127K	623K	665K	1.2M	1.05M	2.16M	4.95M	9.34M
Current Ratio	2.01x	2.23x	10.38x	13.14x	4.26x	5.83x	2.80x	2.14x	14.89x	15.68x
Quick Ratio	1.83x	1.84x	10.38x	13.14x	4.26x	5.83x	2.80x	2.14x	14.89x	15.68x
Cash Conversion Cycle	204.65	93.97	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.78M	422.28K	10.75M	10.86M	18.26M	10.82M	9.75M	8.84M	11.68M	67.11M
Long-Term Debt	0	0	0	0	0	0	0	0	0	49.83M
Capital Lease Obligations	0	0	0	0	0	0	175K	0	130K	2.47M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.78M	422.28K	10.47M	10.86M	18.26M	10.82M	9.58M	8.84M	11.55M	14.81M
Total Liabilities	4.98M	2.13M	12.49M	12.74M	23.23M	19.43M	17.76M	16.15M	23.18M	85.86M
Total Debt+	0	0	0	0	305K	139K	457K	155K	403K	52.83M
Net Debt	-5.49M	-2.73M	-17.1M	-23.1M	-20.43M	-49.09M	-20.85M	-14.45M	-169.28M	-35.1M
Debt / Equity	-	-	-	-	0.02x	0.00x	0.03x	0.01x	0.00x	0.22x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-3.99x	-	-	-230.66x	-	-	-	-	-	-812.43x
Total Equity+	3.22M	3.44M	26.53M	30.41M	14.95M	45.55M	17.79M	10.35M	157.51M	245.11M
Equity Growth %	1.31%	0.07%	6.72%	0.15%	-0.51%	2.05%	-0.61%	-0.42%	14.22%	0.56%
Book Value per Share	25.65	16.61	44.33	21.75	6.57	10.91	3.35	1.23	9.55	6.10
Total Shareholders' Equity	3.22M	3.44M	26.53M	30.41M	14.95M	45.55M	17.79M	10.35M	157.51M	245.11M
Common Stock	14.02K	16.79K	19.24K	32K	45K	80K	80K	8K	32K	46K
Retained Earnings	-86.25M	-98.31M	-113.98M	-127.03M	-157.81M	-182.44M	-213.35M	-237.42M	-276.41M	-452.26M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-211.85K	-159.36K	-73.65K	-93K	0	0	0	0	0	361K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.3M	-13.5M	-9.95M	-11.68M	-17.38M	-25.22M	-27.77M	-20.78M	-24.94M	-69.1M
Operating CF Margin %	-26.58%	-9.3%	0.01%	-	-	-	-	-	-	-
Operating CF Growth %	-1.3%	-0.31%	0.26%	-0.17%	-0.49%	-0.45%	-0.1%	0.25%	-0.2%	-1.77%
Net Income	-15.91M	-12.07M	-12.07M	-11.84M	-30.77M	-24.64M	-30.91M	-24.07M	-38.99M	-175.85M
Depreciation & Amortization	108.23K	131.64K	1.61M	1.96M	1.96M	1.95M	1.96M	1.96M	1.96M	1.99M
Stock-Based Compensation	942.37K	871.27K	880.03K	988K	825K	1.5M	3.28M	2.53M	5.95M	99.96M
Deferred Taxes	3.57M	21.7K	-1.65M	-3.88M	6.96M	-11.64M	0	0	0	0
Other Non-Cash Items	183.32K	-1.64M	1.31M	1M	1.15M	4.62M	-951K	-452K	3.22M	-1.21M
Working Capital Changes	810.06K	-815.43K	-24.07K	82K	2.5M	2.98M	-1.15M	-756K	2.93M	6.02M
Change in Receivables	-156.13K	22.79K	0	-64K	64K	0	0	0	0	0
Change in Inventory	-441.67K	-109.38K	0	0	-64K	0	0	0	0	0
Change in Payables	211.94K	-149.16K	190.63K	249K	1.06M	1.49M	-235K	-1.48M	1.37M	5.67M
Cash from Investing+	-1.32M	-38.68K	378.78K	-180K	528K	-7K	-22K	-13K	0	-225.68M
Capital Expenditures	-305.78K	-38.68K	-2.57K	-8K	-21K	-7K	-22K	-13K	0	-218K
CapEx % of Revenue	0.79%	0.03%	-0%	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-15K	-23.89K	953.94K	-172K	49K	0	0	0	0	0
Cash from Financing+	9.16M	10.77M	23.94M	17.83M	14.48M	53.72M	-128K	14.09M	180.02M	213.03M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	9.16M	-1.39K	-838K	1.52M	0	17K	-120K	-16K	42.16M	14.18M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-10.61M	-13.54M	-9.95M	-11.69M	-17.4M	-25.23M	-27.79M	-20.79M	-24.94M	-69.31M
FCF Margin %	-27.36%	-9.33%	0.01%	-	-	-	-	-	-	-
FCF Growth %	-1.35%	-0.28%	0.26%	-0.17%	-0.49%	-0.45%	-0.1%	0.25%	-0.2%	-1.78%
FCF per Share	-84.38	-65.47	-16.63	-8.36	-7.64	-6.04	-5.23	-2.48	-1.51	-1.73
FCF Conversion (FCF/Net Income)	0.65x	1.12x	0.64x	0.88x	0.56x	1.02x	0.90x	0.86x	0.64x	0.39x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	800	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-493.47%	-362.37%	-104.55%	-46.83%	-135.69%	-81.46%	-97.6%	-171.05%	-46.45%	-87.35%
Return on Invested Capital (ROIC)	-	-1439.31%	-179.97%	-128.07%	-1898.28%	-	-	-	-	-142%
Gross Margin	9%	-4.03%	100.1%	-	-	-	-	-	-	-
Net Margin	-4104.85%	-831.63%	1.01%	-	-	-	-	-	-	-
Debt / Equity	-	-	-	-	0.02x	0.00x	0.03x	0.01x	0.00x	0.22x
Interest Coverage	-3.99x	-	-	-230.66x	-	-	-	-	-	-812.43x
FCF Conversion	0.65x	1.12x	0.64x	0.88x	0.56x	1.02x	0.90x	0.86x	0.64x	0.39x
Revenue Growth	-	274.34%	-107145.41%	100%	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Soleno Therapeutics, Inc. (SLNO) reported $98.7M in revenue for fiscal year 2024.

Soleno Therapeutics, Inc. (SLNO) grew revenue by 0.0% over the past year. Growth has been modest.

Soleno Therapeutics, Inc. (SLNO) reported a net loss of $78.5M for fiscal year 2024.

Dividend & Returns

Soleno Therapeutics, Inc. (SLNO) has a return on equity (ROE) of -87.4%. Negative ROE indicates the company is unprofitable.

Soleno Therapeutics, Inc. (SLNO) had negative free cash flow of $25.7M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Soleno Therapeutics, Inc. (SLNO) 10-Year Financial Performance & Capital Metrics

SLNO • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $0
EBITDA -$186M -371.0%
Net Income -$176M -351.0%
EPS (Diluted) -4.38 -85.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -87.35% -88.0%
ROIC -142%
Debt/Equity 0.22 +8321.9%
Interest Coverage -812.43

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 9 (bottom 9%)
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM40.19%

EPS CAGR

10Y-

5Y-

3Y-

TTM46.1%

ROCE

10Y Avg-103.84%

5Y Avg-74.56%

3Y Avg-75.44%

Latest-77.97%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	387.56K	1.45M	-1.55B	0	0	0	0	0	0	0
Revenue Growth %	-	2.74%	-1071.45%	1%	-	-	-	-	-	-
Cost of Goods Sold+	352.68K	1.51M	1.61M	1.92M	2.3M	2.19M	0	0	0	0
COGS % of Revenue	0.91%	1.04%	-0%	-	-	-	-	-	-	-
Gross Profit+	34.87K	-58.52K	-1.55B	-1.92M	-2.3M	-2.19M	0	0	0	0
Gross Margin %	0.09%	-0.04%	1%	-	-	-	-	-	-	-
Gross Profit Growth %	-	-2.68%	-26565.41%	1%	-0.2%	0.04%	1%	-	-	-
Operating Expenses+	12.19M	13.55M	9.68M	13.73M	20.9M	29.75M	31.53M	24.4M	41.38M	187.67M
OpEx % of Revenue	31.47%	9.34%	-0.01%	-	-	-	-	-	-	-
Selling, General & Admin	7.88M	8.37M	6.61M	6.56M	4.63M	6.56M	10.81M	9.84M	13.48M	105.86M
SG&A % of Revenue	20.33%	5.77%	-0%	-	-	-	-	-	-	-
Research & Development	4.54M	5.18M	3.07M	7.18M	16.27M	23.19M	21.45M	15.27M	25.19M	78.57M
R&D % of Revenue	11.7%	3.57%	-0%	-	-	-	-	-	-	-
Other Operating Expenses	-183.56K	-100.52K	-585.95K	6K	0	0	-731K	-712K	2.71M	3.24M
Operating Income+	-12.16M	-13.61M	-12.17M	-14.3M	-23.2M	-31.95M	-31.53M	-24.4M	-41.38M	-187.67M
Operating Margin %	-31.38%	-9.38%	0.01%	-	-	-	-	-	-	-
Operating Income Growth %	-1.36%	-0.12%	0.11%	-0.17%	-0.62%	-0.38%	0.01%	0.23%	-0.7%	-3.53%
EBITDA+	-12.05M	-13.59M	-10.56M	-12.38M	-20.9M	-29.75M	-29.57M	-22.43M	-39.43M	-185.68M
EBITDA Margin %	-31.1%	-9.37%	0.01%	-	-	-	-	-	-	-
EBITDA Growth %	-1.35%	-0.13%	0.22%	-0.17%	-0.69%	-0.42%	0.01%	0.24%	-0.76%	-3.71%
D&A (Non-Cash Add-back)	108.23K	19.7K	1.61M	1.92M	2.3M	2.19M	1.96M	1.96M	1.96M	1.99M
EBIT	-12.16M	-6.74M	-13.44M	-13.73M	-30.77M	-24.64M	-32.26M	-24.07M	-38.99M	-175.62M
Net Interest Income+	-3.05M	0	0	0	154K	13K	110K	300K	2.58M	11.82M
Interest Income	0	0	0	0	154K	13K	110K	300K	2.58M	12.05M
Interest Expense	3.05M	0	0	62K	0	0	0	0	0	231K
Other Income/Expense	-3.75M	1.59M	-1.27M	2.46M	-7.58M	7.31M	618K	330K	2.4M	11.82M
Pretax Income+	-15.91M	-12.04M	-13.72M	-11.84M	-30.77M	-24.64M	-30.91M	-24.07M	-38.99M	-175.85M
Pretax Margin %	-41.05%	-8.3%	0.01%	-	-	-	-	-	-	-
Income Tax+	0	21.7K	-1.65M	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1.14%	1.13%	1%	1%	1%	1%	1%	1%
Net Income+	-15.91M	-12.07M	-15.67M	-13.34M	-30.77M	-24.64M	-30.91M	-24.07M	-38.99M	-175.85M
Net Margin %	-41.05%	-8.32%	0.01%	-	-	-	-	-	-	-
Net Income Growth %	-0.15%	0.24%	-0.3%	0.15%	-1.31%	0.2%	-0.25%	0.22%	-0.62%	-3.51%
Net Income (Continuing)	-15.91M	-6.74M	-11.79M	-11.84M	-30.77M	-24.64M	-30.91M	-24.07M	-38.99M	-175.85M
Discontinued Operations	0	-5.33M	-3.59M	-1.49M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-126.58	-58.35	-26.18	-9.54	-15.78	-3.68	-5.81	-2.87	-2.36	-4.38
EPS Growth %	0.85%	0.54%	0.55%	0.64%	-0.65%	0.77%	-0.58%	0.51%	0.18%	-0.86%
EPS (Basic)	-126.58	-58.35	-26.18	-9.54	-15.78	-3.68	-5.81	-2.87	-2.36	-4.38
Diluted Shares Outstanding	125.68K	206.77K	598.52K	1.4M	2.28M	4.17M	5.32M	8.4M	16.49M	40.18M
Basic Shares Outstanding	125.68K	206.77K	598.52K	1.4M	2.28M	4.17M	5.32M	8.4M	16.49M	40.18M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.4M	3.8M	17.99M	24.67M	21.14M	50.24M	22.42M	15.65M	171.36M	293.89M
Cash & Short-Term Investments	5.49M	2.73M	17.1M	24.08M	20.73M	49.22M	21.3M	14.6M	169.68M	291.44M
Cash Only	5.49M	2.73M	17.1M	23.1M	20.73M	49.22M	21.3M	14.6M	169.68M	87.93M
Short-Term Investments	0	0	0	978K	0	0	0	0	0	203.51M
Accounts Receivable	156.13K	133.34K	0	64K	0	0	0	0	0	0
Days Sales Outstanding	147.04	33.55	-	-	-	-	-	-	-	-
Inventory	551.01K	660.39K	0	0	0	0	0	0	0	0
Days Inventory Outstanding	570.25	159.7	-	-	-	-	-	-	-	-
Other Current Assets	35K	695.39K	551K	0	0	0	0	1.04M	1.68M	2.45M
Total Non-Current Assets+	1.8M	1.76M	21.03M	18.48M	17.03M	14.74M	13.13M	10.85M	9.33M	37.08M
Property, Plant & Equipment	85.75K	102.56K	22.89K	12K	444K	158K	454K	157K	419K	2.98M
Fixed Asset Turnover	4.52x	14.15x	-67861.13x	-	-	-	-	-	-	-
Goodwill	718K	718K	125.53K	0	0	0	0	0	0	0
Intangible Assets	916.81K	817.47K	20.41M	18.47M	16.52M	14.58M	12.64M	10.69M	8.75M	6.8M
Long-Term Investments	0	0	0	0	0	0	0	0	0	27.21M
Other Non-Current Assets	76.34K	125.53K	591.92K	0	59K	0	40K	0	165K	83K
Total Assets+	8.2M	5.56M	39.02M	43.15M	38.17M	64.98M	35.55M	26.5M	180.69M	330.97M
Asset Turnover	0.05x	0.26x	-39.80x	-	-	-	-	-	-	-
Asset Growth %	-0.02%	-0.32%	6.01%	0.11%	-0.12%	0.7%	-0.45%	-0.25%	5.82%	0.83%
Total Current Liabilities+	3.19M	1.71M	1.73M	1.88M	4.96M	8.62M	8.01M	7.31M	11.51M	18.75M
Accounts Payable	495.34K	410.51K	633K	934K	2M	3.49M	3.25M	1.78M	3.15M	8.88M
Days Payables Outstanding	512.64	99.28	143.42	177.65	317.01	580.44	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	2.18M	246.4K	127K	623K	665K	1.2M	1.05M	2.16M	4.95M	9.34M
Current Ratio	2.01x	2.23x	10.38x	13.14x	4.26x	5.83x	2.80x	2.14x	14.89x	15.68x
Quick Ratio	1.83x	1.84x	10.38x	13.14x	4.26x	5.83x	2.80x	2.14x	14.89x	15.68x
Cash Conversion Cycle	204.65	93.97	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.78M	422.28K	10.75M	10.86M	18.26M	10.82M	9.75M	8.84M	11.68M	67.11M
Long-Term Debt	0	0	0	0	0	0	0	0	0	49.83M
Capital Lease Obligations	0	0	0	0	0	0	175K	0	130K	2.47M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	1.78M	422.28K	10.47M	10.86M	18.26M	10.82M	9.58M	8.84M	11.55M	14.81M
Total Liabilities	4.98M	2.13M	12.49M	12.74M	23.23M	19.43M	17.76M	16.15M	23.18M	85.86M
Total Debt+	0	0	0	0	305K	139K	457K	155K	403K	52.83M
Net Debt	-5.49M	-2.73M	-17.1M	-23.1M	-20.43M	-49.09M	-20.85M	-14.45M	-169.28M	-35.1M
Debt / Equity	-	-	-	-	0.02x	0.00x	0.03x	0.01x	0.00x	0.22x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-3.99x	-	-	-230.66x	-	-	-	-	-	-812.43x
Total Equity+	3.22M	3.44M	26.53M	30.41M	14.95M	45.55M	17.79M	10.35M	157.51M	245.11M
Equity Growth %	1.31%	0.07%	6.72%	0.15%	-0.51%	2.05%	-0.61%	-0.42%	14.22%	0.56%
Book Value per Share	25.65	16.61	44.33	21.75	6.57	10.91	3.35	1.23	9.55	6.10
Total Shareholders' Equity	3.22M	3.44M	26.53M	30.41M	14.95M	45.55M	17.79M	10.35M	157.51M	245.11M
Common Stock	14.02K	16.79K	19.24K	32K	45K	80K	80K	8K	32K	46K
Retained Earnings	-86.25M	-98.31M	-113.98M	-127.03M	-157.81M	-182.44M	-213.35M	-237.42M	-276.41M	-452.26M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-211.85K	-159.36K	-73.65K	-93K	0	0	0	0	0	361K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-10.3M	-13.5M	-9.95M	-11.68M	-17.38M	-25.22M	-27.77M	-20.78M	-24.94M	-69.1M
Operating CF Margin %	-26.58%	-9.3%	0.01%	-	-	-	-	-	-	-
Operating CF Growth %	-1.3%	-0.31%	0.26%	-0.17%	-0.49%	-0.45%	-0.1%	0.25%	-0.2%	-1.77%
Net Income	-15.91M	-12.07M	-12.07M	-11.84M	-30.77M	-24.64M	-30.91M	-24.07M	-38.99M	-175.85M
Depreciation & Amortization	108.23K	131.64K	1.61M	1.96M	1.96M	1.95M	1.96M	1.96M	1.96M	1.99M
Stock-Based Compensation	942.37K	871.27K	880.03K	988K	825K	1.5M	3.28M	2.53M	5.95M	99.96M
Deferred Taxes	3.57M	21.7K	-1.65M	-3.88M	6.96M	-11.64M	0	0	0	0
Other Non-Cash Items	183.32K	-1.64M	1.31M	1M	1.15M	4.62M	-951K	-452K	3.22M	-1.21M
Working Capital Changes	810.06K	-815.43K	-24.07K	82K	2.5M	2.98M	-1.15M	-756K	2.93M	6.02M
Change in Receivables	-156.13K	22.79K	0	-64K	64K	0	0	0	0	0
Change in Inventory	-441.67K	-109.38K	0	0	-64K	0	0	0	0	0
Change in Payables	211.94K	-149.16K	190.63K	249K	1.06M	1.49M	-235K	-1.48M	1.37M	5.67M
Cash from Investing+	-1.32M	-38.68K	378.78K	-180K	528K	-7K	-22K	-13K	0	-225.68M
Capital Expenditures	-305.78K	-38.68K	-2.57K	-8K	-21K	-7K	-22K	-13K	0	-218K
CapEx % of Revenue	0.79%	0.03%	-0%	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-15K	-23.89K	953.94K	-172K	49K	0	0	0	0	0
Cash from Financing+	9.16M	10.77M	23.94M	17.83M	14.48M	53.72M	-128K	14.09M	180.02M	213.03M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	9.16M	-1.39K	-838K	1.52M	0	17K	-120K	-16K	42.16M	14.18M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-10.61M	-13.54M	-9.95M	-11.69M	-17.4M	-25.23M	-27.79M	-20.79M	-24.94M	-69.31M
FCF Margin %	-27.36%	-9.33%	0.01%	-	-	-	-	-	-	-
FCF Growth %	-1.35%	-0.28%	0.26%	-0.17%	-0.49%	-0.45%	-0.1%	0.25%	-0.2%	-1.78%
FCF per Share	-84.38	-65.47	-16.63	-8.36	-7.64	-6.04	-5.23	-2.48	-1.51	-1.73
FCF Conversion (FCF/Net Income)	0.65x	1.12x	0.64x	0.88x	0.56x	1.02x	0.90x	0.86x	0.64x	0.39x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	800	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-493.47%	-362.37%	-104.55%	-46.83%	-135.69%	-81.46%	-97.6%	-171.05%	-46.45%	-87.35%
Return on Invested Capital (ROIC)	-	-1439.31%	-179.97%	-128.07%	-1898.28%	-	-	-	-	-142%
Gross Margin	9%	-4.03%	100.1%	-	-	-	-	-	-	-
Net Margin	-4104.85%	-831.63%	1.01%	-	-	-	-	-	-	-
Debt / Equity	-	-	-	-	0.02x	0.00x	0.03x	0.01x	0.00x	0.22x
Interest Coverage	-3.99x	-	-	-230.66x	-	-	-	-	-	-812.43x
FCF Conversion	0.65x	1.12x	0.64x	0.88x	0.56x	1.02x	0.90x	0.86x	0.64x	0.39x
Revenue Growth	-	274.34%	-107145.41%	100%	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Soleno Therapeutics, Inc. (SLNO) reported $98.7M in revenue for fiscal year 2024.

Soleno Therapeutics, Inc. (SLNO) grew revenue by 0.0% over the past year. Growth has been modest.

Soleno Therapeutics, Inc. (SLNO) reported a net loss of $78.5M for fiscal year 2024.

Dividend & Returns

Soleno Therapeutics, Inc. (SLNO) has a return on equity (ROE) of -87.4%. Negative ROE indicates the company is unprofitable.

Soleno Therapeutics, Inc. (SLNO) had negative free cash flow of $25.7M in fiscal year 2024, likely due to heavy capital investments.